Morgan Stanley Aadi Bioscience, Inc. Transaction History
Morgan Stanley
- $1.39 Trillion
- Q4 2024
A detailed history of Morgan Stanley transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Morgan Stanley holds 12,761 shares of AADI stock, worth $26,798. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,761
Previous 2,411
429.28%
Holding current value
$26,798
Previous $4,000
900.0%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding AADI
# of Institutions
57Shares Held
15.6MCall Options Held
15KPut Options Held
3.1K-
Avoro Capital Advisors LLC New York, NY2.85MShares$5.98 Million0.13% of portfolio
-
Qvt Financial LP New York, NY2.31MShares$4.86 Million0.72% of portfolio
-
Bml Capital Management, LLC Zionsville, IN2.1MShares$4.41 Million4.12% of portfolio
-
Acuta Capital Partners, LLC Belmont, CA1.85MShares$3.88 Million8.31% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.15MShares$2.41 Million1.96% of portfolio
About Aadi Bioscience, Inc.
- Ticker AADI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,016,800
- Market Cap $44.1M
- Description
- Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...